

1 ***Original article***

2 **Difference in presentation, outcomes, and hospital epidemiologic trend of COVID-19** 3 **among first, second, and third waves in Dhaka Medical College**

4 **Authors:**

- 5 1. **Dr. Reaz Mahmud FCPS, MD**, Assistant Professor, Department of Neurology, Dhaka
6 Medical College. Dhaka, Bangladesh. Phone-+8801912270803. [E-mail-](mailto:reazdmc22@yahoo.com)
7 reazdmc22@yahoo.com and rmahmudneuro@dmc.gov.bd. ORCID ID-0000-0002-9427-
8 1746.
- 9 2. **Dr. Md. Ashikul Islam, MD**, Indoor Medical Officer, National Institute of
10 neurosciences and Hospital. Dhaka, Bangladesh. phone: 01737104013, [mail-](mailto:ashikdmc62@gmail.com)
11 ashikdmc62@gmail.com, ORCID ID -0000-0001-8331-1362
- 12 3. **Dr. Md. Emdadul Haque, MD**, Medical officer, Department of Neurology, Dhaka
13 Medical College. Dhaka, Bangladesh. phone: 0714560256, [mail-](mailto:dr.emdadmithu@gmail.com)
14 dr.emdadmithu@gmail.com, ORCID ID 0000-0001-6870-6075
- 15 4. **Dr. Md. Dewan Azmal Hussain**, Assistant professor, National Institute of Chest
16 diseases and Hospital, Phone: +8801819449812, Mail: azmal.dr@gmail.com
- 17 5. **Dr. Mohammad Rafiqul Islam**, Associate professor, Department of Medicine, shaheed
18 Suhrawardy Medical college. Phone-+8801624413595, Mail: dr Rafiq73@yahoo.com.
- 19 6. **Dr. Farhana Binte Monayem, MBBS**, Medical officer, Sarkari karmachari Hospital.
20 Dhaka, Bangladesh. Phone-+8801920155971. Mail-farhanabintemonayem@gmail.com.
21 ORCID ID-0000-0001-5023-0638.
- 22 7. **Dr. Mostofa Kamal, MD**, Assistant professor, Department of Medicine, Dhaka Medical
23 College. Phone-+8801711582960, mail- mkamal052@gmail.com

- 24 8. **Dr. Hashmi Sina MRCP, MD**, Assistant professor, Department of Neurology, Dhaka
25 Medical College. Dhaka, Bangladesh. Phone-+88017189675269, E-mail:
26 hashmi.sina49@gmail.com
- 27 9. **Dr. Mohammad Fakhrul Islam, MD**, Assistant professor, Department of Neurology,
28 Dhaka Medical College. Dhaka, Bangladesh. Phone-+88001937859810, mail-
29 fakhrulislam.work@gmail.com.
- 30 10. **Dr. Ponkaj Kanti Datta**, Assistant professor, Department of Medicine, Dhaka Medical
31 College, Dhaka, Bangladesh. Phone number: +8801711069701. Mail-
32 ponkajdatta@yahoo.com. ORCID ID: [0000-0002-4508-4549](https://orcid.org/0000-0002-4508-4549)
- 33 11. **Dr. S.K. Jakaria Been Sayeed, MRCP**, Indoor Medical Officer, National Institute of
34 neurosciences and Hospital. Dhaka, Bangladesh Phone- +8801783335147. Mail-
35 skjakaria1@gmail.com. ORCID ID-0000-0003-1173-4248.
- 36 12. **Dr. Sabbir Ahmed Dhali, MD**, Registrar, Department of Neurology, Dhaka Medical
37 College. Dhaka, Bangladesh. Phone-+8801720015583. Mail-dr.sabbirdhali@gmail.com.
- 38 13. **Dr. Khairul Islam, FCPS**. Junior consultant, Department of Medicine, Dhaka Medical
39 College, Dhaka, Bangladesh. phone-+8801717696207. Mail-
40 khairul0696207@gmail.com, ORCHID: 00 00000188716270.
- 41 14. **Dr. Rifat Hossain Ratul**, Medical Officer, COVID-19 post-acute care and follow-up
42 clinic, Dhaka Medical College. Phone:01631907154, Mail: dr.ratulrifat@gmail.com.
- 43 15. **Dr. SK Md. Rubaed Hossain**, Research Assistant, Stroke registry, Department of
44 Neurology, Dhaka Medical College. Dhaka, Bangladesh, Phone: 01680888637, **Mail:**
45 dr.rubaed94@gmail.com.

- 46 16. **Habib Naziat Prince**, MSC, Research Assistant, North South University, **phone:**
47 +8801647237397. Mail- habib.52statru@gmail.com
- 48 17. **Dr. Ahmed Hossain Chowdhury**, MD, Associate Professor, Department of Neurology,
49 Dhaka Medical College. Dhaka, Bangladesh. Cell no: +88001712257206. [Mail:](mailto:ahmedssmc17@yahoo.com)
50 ahmedssmc17@yahoo.com.
- 51 18. **Dr. Kazi Gias Uddin Ahmed**, Associate Professor and Head, Department of Neurology,
52 Dhaka Medical College. Dhaka, Bangladesh. Phone-01611272277 mail-
53 kazi17k43@gmail.com. [ORCID ID-0000-0002-0163-8271](https://orcid.org/0000-0002-0163-8271)
- 54 19. **Dr. Md.Titu Miah**, Principal and Professor of Medicine, Department of Medicine,
55 Dhaka Medical College, Dhaka, Bangladesh. **Mobile:** +8801711591770. Mail:
56 titum21@gmail.com
- 57 20. **Dr. Md. Mujibur Rahman FCPS, MD, FACP** Professor, Department of Medicine,
58 Bangabandhu Sheikh Mujib Medical University, Dhaka. Bangladesh Phone-
59 01711525406 [Mail-mmrahman61@gmail.com](mailto:mmrahman61@gmail.com). ORCID Identifier: 0000-0002-4381-
60 1511.

61 **Data availability statement:** The data will be within the paper and uploaded as supplementary
62 file.

63 **A funding statement:** This research received grant from Director General of Health Services,
64 Government of the peoples' republic of Bangladesh.

65 **Conflict of interest disclosure:** The authors declare that there is no conflict of interest.

66 **Ethics approval statement:** The Institutional Ethical Committee of Dhaka Medical College
67 approved the study (ERC-DMC/ECC/2021/55).

68 **Patient consent statement:** As we mainly reviewed hospital data, there was no scope for written
69 consent. We took verbal permission from the patient for post-covid follow-up.

70 **Permission to reproduce material from other sources:** Not applicable

71 **Clinical trial registration:** Not applicable

72

73

74 **Corresponding Author:**

75 **Dr. Reaz Mahmud,**

76 Assistant Professor, Department of Neurology, Dhaka Medical College. Dhaka, Bangladesh.

77 Phone-+8801912270803.

78 [E-mail-reazdmc22@yahoo.com](mailto:reazdmc22@yahoo.com). rmahmudneuro@dmc.gov.bd.

79 ORCID ID-0000-0002-9427-1746

80

81

82

83

84

85

86

87

88

89

90

91

92

93 **Difference in presentation, outcomes, and hospital epidemiologic trend of COVID-19**

94 **among first, second, and third waves in Dhaka Medical College**

95 **Abstract:**

96 **Background**

97 This study aimed to examine the differences in epidemiologic and disease aspects among
98 patients with COVID-19

99 **Methods:**

100 We reviewed the hospital records between April 2020 and September 2021 and followed up on
101 the patients for post-COVID complications.

102 **Findings:**

103 Older adult patients were predominantly affected during the first and second waves, followed by
104 middle-aged patients. Men were predominantly admitted, considering the three waves; although
105 more women were admitted in the second wave. Cough was more common in the second and
106 third waves than in the first wave 522 (59.7%). Respiratory distress was the most common in the
107 third wave, 251(67.1%), and least common in the first wave 403 (46.1%). Anosmia was more
108 common in the third wave 116 (31.2%). In the third wave, patients presenting in a critical state
109 23 (6.2%) and severe disease 152 (40.8%) were more common. The hospital admission median
110 (IQR) was longer in the first wave, 12 (8–20), than in other waves. More patients were admitted
111 in the first wave (52%) than in the other waves, and patients received more oxygen in the third
112 wave (75%) than in the other waves. Death occurred more commonly in the first wave (51%)
113 than in the other waves. Patients were investigated more commonly in the first and third waves

114 than in the second wave. The positivity rate was high in the third wave (22.8%) than in other
115 waves. In the third wave, the positivity rate was higher in women (24.3%) than in men. Post-
116 covid cough increased in the second wave and fatigue was higher in the third wave than in other
117 waves. Tiredness and memory loss was greater during the second wave than in other waves.

118 **Conclusion:**

119 This study revealed that the presenting symptoms, outcomes, and epidemiologic trends differed
120 during the COVID-19 waves.

121 **Introduction**

122 On December 31 World Health Organization (WHO) formally reported a case of atypical
123 pneumonia in Wuhan City, China [1], which was later named coronavirus disease-19 (COVID-
124 19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [2]. On March
125 11, 2020, WHO declared the novel coronavirus (COVID-19) outbreak a global pandemic [3].

126 The WHO classified the phases of the pandemic as phases 1–3(predominantly animal infection,
127 few human infections), phase 4(sustained human-to-human infection), phases 5 and 6
128 (widespread human infection), post-peak (possibility of recurrent events), and post-pandemic
129 (disease activity at seasonal level) [4]. Most of the worst pandemics lasted for several years [5].

130 After studying the transmission dynamics of SARS-CoV-2, researchers postulated that it would
131 reach long-term circulation within the next five years [6]. Experience in the last 2 years has
132 revealed that resurgence as “waves” is common [4], and the overall pattern of the coronavirus
133 pandemic has been a series of increased COVID-19 waves: which gradually declines. Several
134 outbreaks of illnesses have occurred in various parts of the world. Europe entered its third phase
135 in March 2021 [7], and the United States is likely to experience the 4th wave [8]. The reason for

136 the seasonal variation in transmission, duration of immunity, degree of cross-immunity between
137 SARS-CoV-2 and other coronaviruses, intensity and timing of control measures [7], and not the
138 least viral mutation can all explain the wave and gradual decline of cases (waves of the disease).
139 [10]. SARS-CoV-2 has mutated at a pace of about 1–2 mutations per month throughout the
140 current global crisis [11]. A variant of SARS-CoV-2 with the *D614G* mutation emerged in China
141 in late January and early February 2020 and immediately became the dominant form of the virus
142 circulating globally [10]. Subsequently, several mutations were recognized as mutations of
143 concern, naming the UK variant known as 501Y. V1, VOC 202012/01, and B.1.1.7, a South
144 African variant known as the 501Y. V2, or B.1.351, a Brazilian variant known as 501Y. V3 or
145 P.1 lineage [11, 12, 13], and the Indian variant B.1.617 (double mutant) [14]. The Indian variant
146 gave rise to India's second wave and stressed its health system. In terms of test positivity rates
147 (TPRs) and case fatality rates (CFRs), the epidemiologic characteristics seem to differ from those
148 of the first wave [15]. Bangladesh reported the peak of the second wave in late February 2021
149 and the third wave in June 2021 [16]. In the second wave, death rate increased among the young
150 [17]. The African variant was responsible for more than 80% of the second wave, while the delta
151 variant was responsible for 78% of the third wave [17,18]. Preliminary reports of various SARS-
152 CoV-2 mutant strains show transmissibility, severity, and case mortality diversity. The initial
153 study about the African variant reported no significant correlation between severe disease and
154 outcomes. However, higher transmissibility is possible. The mutant virus behavior in
155 Bangladeshi populations remains largely unknown.

156 Therefore, this study aimed to systematically and scientifically observe the difference in the
157 presentation and outcome of patients with COVID-19 between the first, second, and third waves.

158 Additionally, we examined the positivity rate, hospital admission rate, and death rate in
159 outpatient department patients.

160 **Materials and Methods**

161 This study aimed to examine differences in the epidemiology of COVID-19 in the first, second,
162 and third waves. We aimed to find if there were any variations in the symptoms, disease severity,
163 case fatality, length of hospital stay, frequency of patients requiring oxygen therapy, and referrals
164 to the intensive care unit (ICU). We reviewed the outpatient data for clinic attendance, hospital
165 admission rate, and death in the outpatient department. We examined the virology laboratory
166 data to observe differences in the positivity rate, number of tests, and age and sex. We reviewed
167 inpatient hospital data for rates of hospital admission and death. We found differences in
168 complications of COVID-19 in patients followed up for at least 6 months after hospital discharge
169 during the first, second, and third waves of COVID-19.

170 **Study area and period**

171 The study was conducted at Dhaka Medical College Hospital between January 01, 2021, and
172 June 20, 2022.

173 **Study design**

174 We conducted a cross-sectional study and a review of the hospital records. We reviewed the
175 hospital records of outpatients, inpatients, and virology departments. We examined the patients'
176 medical. Some patients were followed up for at least 6 months after discharge for post-COVID-
177 19 complications. The telephone interviews followed pre-specified telephone interview
178 guidelines.

179 **Source population**

180 The Dhaka Medical College Hospital inpatient were the source population.

181 **Study population**

182 The study population included inpatients and patients who called back at least 6 months after
183 follow-up.

184 **Eligibility criteria**

185 The study included patients' records, containing important demographics such as age, sex, area
186 of residence, telephone number, complete treatment sheet, admission and discharge date, and at
187 least a brief history. Patients more than 18 years of age, with RT-PCR positive test results
188 irrespective of the severity of the disease admitted between April 2020 and September 2022 were
189 included in this study for analysis and follow-up.

190 **Sample size determination**

191 The sample size was calculated using the formula below, and the hypothesis was that there was
192 no variation in presentation between the COVID-19 waves in Bangladesh during the pandemic:

$$193 \quad n = \frac{[Z_{\alpha}\sqrt{2p(1-p)} + Z_{\beta}\sqrt{p_1(1-p_1) + p_2(1-p_2)}]^2}{(p_1 - p_2)^2}$$

194 Here, $Z_{\alpha}=1.96$ Z value of standard normal distribution at 95% confidence interval,
195 P_1 =prevalence of severe infection in the first wave, P_2 =Prevalence of severe disease in the
196 second wave, $RR=1.5$ [risk ratio], $P_2= 0.12$; in one study in Bangladesh, the prevalence of severe
197 infection was 11.5% [19], $P_1=RR \times p_2=0.18$, $Z_{\beta}=0.84$ at 80% power, $P= (p_1+p_2) \div 2=0.15$. Thus,
198 the estimated sample size was 240 for each wave.

199 **Sampling technique and procedure**

200 Cluster sampling methods were used. We compiled a list of all wards where patients with
201 COVID-19 had been admitted. We selected one male ward and one female ward. We
202 subsequently reviewed all records that met the inclusion and exclusion criteria. We selected post-
203 COVID follow-up with non-random sampling methods.

204 **Study variables**

205 The variables included in the study were

206 **Demographic variable:** Age of the respondents in years and sex

207 **Presenting features of COVID-19:** Fever, cough, respiratory distress, sore throat, nausea,
208 vomiting, diarrhea, and body ache.

209 **Investigations in COVID-19 state:** Total blood count, CRP, D-dimer, creatinine, and ferritin
210 levels.

211 **COVID-19-severity:** COVID-19 positivity, symptoms in case of COVID-19 positivity
212 (asymptomatic, mild, moderate, severe, or critical)

213 **Duration:** Duration between symptom onset and hospital admission, length of hospital stay.

214 **Post-COVID-19 conditions:** Fatigue, cough, respiratory distress, insomnia, etc.

215 **Outcome-related questions:** Discharged and death. Oxygen requirement, ICU referral

216 **Functional impact:** We examined functional implications in the post-covid state for at least 6
217 months for overall functional status, fatigue score, and depression score.

218 **Operational definition:** Confirmed Covid-19, and its different severities were defined according
219 to the WHO and National guidelines [19, 20].

220 **Case fatality rate:**

$$\text{CFR} = \frac{\text{NUMBER OF TOTAL DEATH SURING THE SAME PERIOD IN THE SAME WARD}}{\text{NUMBER OF TOTAL ADMISSION IN THE DEFINED PERIOD IN THE SELECTED WARD}} \times 100$$

223

224 **Duration of hospital stay:** The total period from the day of admission to the day of discharge.

225 **Waves of infection:** The first, second, and third waves extend between April 2020 to January

226 2020, February 2021 and May 2021, and June 2021 and September 2021, respectively [21,22].

227 **Post-COVID-19 condition: According to the Center for Disease Control, USA [23]**

228 Post-COVID conditions include a wide range of new, returning, or ongoing health problems that

229 people experience after contracting the SARS-CoV-2 causing COVID-19.

230 **Post-COVID fatigue:** The diagnostic criteria for post-COVID-19 fatigue were developed

231 according to the United States Institute of Medicine symptom criteria [24].

232 The Chalder Fatigue Scale [25], the Karnofsky Performance Status Scale [26], and the

233 depression scale were used to assess fatigue severity, overall functional status, and depression

234 [27].

235 **Data collection instrument**

236 For patients admitted to the hospital, data were collected on a data collection sheet. A telephone

237 directory was used for Post COVID-19 follow-up. We collected data from reports of outpatient,

238 inpatient, and virology departments.

239 **Data Collection procedure**

240 We collected all patients' files from the hospital record unit in the selected ward. Each file was

241 evaluated by one data collector and researcher. The completed data collecting sheet contains a

242 list of all available information. We obtained no specific procedure for missing data and

243 excluded files that did not contain essential information, such as patient demographics,

244 admission date, and discharge date. We collected the phone number from the hospital records
245 and interviewed the patients for post-covid -19 complications at least 6 months after recovery.
246 We collected data from the outpatient, inpatient, and virology departments using the Excel
247 datasheet, which contains the patient's name, age, sex, date of attendance, outcome, admission,
248 death, discharge, positive or negative status, etc.

249 **Data Quality Control**

250 Each data sheet was reviewed by two researchers; disagreements were resolved through
251 discussion. We removed responses where respondents provided contradictory answers. Because
252 each patient was coded and had a specified hospital record number, there was no scope for
253 double responses.

254 **Data Processing and Analysis**

255 R (v4.1.1) was used to process data. We performed a network analysis with a tidy verse and q
256 graph. Qualitative data with normal distribution were expressed as means (SD), while non-
257 normal data were expressed as medians (IQR). We divided the respondents into groups of first,
258 second, and third waves. We used the chi-square test to calculate quantitative data and one-way
259 ANOVA to calculate quantitative data. A needed we used a post hoc analysis with Bonferroni
260 adjustment, Dunn test, and Tukey's test. We determined epidemiological trends in the EXECL
261 sheet. The p-value for statistical significance was set at <0.05. We did not impute any missing
262 values, and they were included in the analysis.

263 **Ethical consideration**

264 The Institutional Ethical Committee of Dhaka Medical College approved this study (ERC-
265 DMC/ECC/2021/55). As we mainly reviewed the hospital data, there was no need for written
266 consent. The patients provided verbal consent for post-covid follow-up.

267 **Results**

268 We reviewed 1766 patient records and included 1597 patients' data for analysis in this mixed
269 study of retrospective hospital review of hospital data and cross-sectional follow-up of patients
270 admitted for post-COVID-19 complications. From these patients we followed 600 patients over
271 the telephone for post-COVID-19 complications. Between April 2020 and September 2021, and
272 38578 patients visited the outpatient department, 24501 patients were admitted, 57857 were
273 tested for treatment at the virology department (Suppliment1).

274 **Table 1: Demographic characteristics and co-morbidity of the admitted patients in the**
275 **three waves**

Variable	Categories	Total patient (n=1595) (N)	First wave ^a (n=874) (N) %	Second wave ^b (n=349) (N) %	Third wave ^c (n=372) (N) %	P value
Age (n=1597), mean (SD)		47.91(15.67)	43.82(14.31)	50.79(15.95)	54.62(15.61)	<0.001
	<40 years	512 32.1%	364 41.6%	84 24.1%	64 17.2%	

Age (n= 1595)						<0.001
	40-60 years	652 40.8%	366 41.9%	139 39.8%	147 39.5%	
	60+ years	431 27.02%	144 54.8%	126 36.1%	161 43.3%	
sex (n= 1595)	Female	627 39.31%	283 32.4%	191 54.7%	153 41.0%	<0.001
	Male	968 60.68%	590 67.6%	158 45.3%	220 59.0%	
Fever (n= 1595)	Present	1366 85.6%	738 84.4%	296 85.1%	332 89.0%	0.1
Cough (n= 1595)	Present	1040 65.2%	522 59.7%	228 65.5%	290 78.0%	<0.001
Running nose (n= 1595)	Present	206 12.9%	143 16.4%	16 4.6%	47 12.6%	<0.001
Respiratory distress (n= 1595)	Present	848 (53.1)	403 46.1%	194 55.7%	251 67.1%	<0.001
Sore throat (n= 1595)	Present	278 17.4%	198 22.7%	33 9.5%	47 12.6%	<0.001

Hoarseness of voice (n= 1595)	Present	24 1.5%	11 1.3%	5 1.4%	8 2.1%	0.50
Chest pain (n= 1595)	Present	107 6.7%	52 6.0%	19 5.4%	36 9.6%	0.03
Diarrhea (n= 1595)	Present	152 9.5%	74 8.5%	18 5.2%	60 16.1%	<0.001
Vomiting (n= 1595)	Present	96 6.1%	29 3.3%	8 2.3%	59 15.9%	<0.001
Anorexia (n= 1594)	Present	274 17.1%	123 14.1%	38 11.0%	113 30.2%	<0.001
Anosmia (n= 1593)	Present	301 18.8%	158 18.1%	27 7.8%	116 31.2%	<0.001
Headache (n= 1583)	Present	252 15.7%	145 16.6%	25 7.2%	82 22.5%	<0.001
Lethargy (n= 1597)	Present	436	231 26.4%	106 30.4%	99 26.5%	0.35
Body ache (n= 1596)	Present	286	107 12.2%	87 25.0%	92 24.6%	<0.001
Presenting	Critical ^f	25 1.5%	0 0.0%	2 0.6%	23 6.2%	<0.001
	Mild ^g	747 29.7%	422 48.3%	216 61.9%	109 29.2%	

severity ^d (n= 1595)	Moderate ^h	648	443	116	89	
		40.6%	50.7%	33.2%	23.9%	
	Severe ⁱ	175	8	15	152	
Ultimate severity ^e (n= 1595)	Critical ^f	107	32	3	72	<0.001
			3.7%	0.9%	19.3%	
	Mild ^g	627	365	183	79	
		41.8%	52.9%	21.1%		
Moderate ^h	589	383	128	78		
		43.8%	37.0%	20.9%		
Severe ⁱ	271	94	32	145		
		10.8%	9.2%	38.8%		
Diabetes (n= 1151)	Present	531	216	136	179	<0.001
		33.2%	28.4%	38.8%	48.1%	
Hypertension (n= 1154)	Present	532	182	142	208	<0.001
		33.3	24.5%	40.6%	55.9%	
Asthma (n= 931)	Present	114	57	30	27	<0.001
		7.1%	8.0%	8.5%	16.0%	
IHD (n= 930)	Present	123	29	31	63	<0.001
		7.7	4.1%	8.8%	16.9%	
Renal disease	Present	103	24	32	47	<0.001
		6.4%	3.4%	9.1%	12.6%	

(n= 926)						
<ul style="list-style-type: none">a- From April 2020 to January 2021,b- From February 2021 to May 2021c- From June 2021 to September 2021d- The severity of the patient at the time of hospital admissione- The severity of the patient in the course of the hospital staysf- Critical: Patient requiring high flow oxygen or mechanical ventilationg- Mild: Patients having mild symptoms of upper respiratory tract viral infection, including mild fever, cough (dry), sore throat, nasal congestion, malaise, headache, muscle pain, anosmia, or malaise;h- Moderate: the patient has respiratory symptoms such as cough and shortness of breath are present without signs of severe pneumonia (tachypnea >30 breaths/min and hypoxia: oxygen saturation <90% on room air).i- Severe: Patients with severe pneumonia require supplemental oxygen through nasal canal, facemask, or face mask with reservoir.						

276

277

278 The mean age (SD) of the hospital-admitted patients was 47.91(15.67) years, with patients in the
279 and third waves being higher than those in the first wave ($p < 0.001$). Patients above 60 years
280 were mainly involved in the first wave 144 (54.8%), the 40–60 age group was primarily involved
281 in the second wave 139 (39.8%), and those above 60 years were more likely to be infected in the
282 third wave 161 (43.3%).

283 Men were predominantly admitted 968 (60.68%). However, in the second wave, the number of
284 women, 191 (54.7%), was higher.

285 Fever was present in 1366 (85.6%) patients and did not differ among the three waves ($p = 0.1$).

286 Cough was more prevalent in the second 288 (65.5%) and third waves 290 (78%) than in the first
287 wave 522 (59.7%). Running nose was most prevalent in the first wave, 143 (16.4%), and least
288 prevalent in the second wave, 16 (4.6%). Respiratory distress was the most prevalent in the third
289 wave, 251 (67.1%), and the least prevalent in the first wave, 403 (46.1%). Sore throat occurred
290 more prevalent in the first wave 198 (22.7%) than in the other waves. Diarrhea 60 (16.1) and

291 vomiting 59 (15.9%) were the most prevalent in the third wave. Anosmia was more prevalent in
292 the third wave 116 (31.2%) than in other waves and less frequently in the second wave 27 (7.8%)
293 than in other waves. However, headache was more prevalent in the third 82 (22.5%) and first
294 wave 145 (16.6%) than in the second wave. Body aches occurred more commonly in the second
295 87 (25%) and third 92 (24.6%) waves than in the first wave. (Table 1)

296 Patients that presented in a critical condition 23 (6.2%) and severe disease 152 (40.8%) were
297 more prevalent in the third wave than in other waves. In the second wave, most cases were mild
298 216 (61.9%). During the hospital stay, the severity of the patient's severity changed, and in the
299 third wave, 72 (19.3%) critical and 145 (38.8%) severe diseases emerged. Mild-to-moderate
300 illness was more common in the first and second waves than in the third wave.

301 Diabetes was more common among admitted patients in the second 136 (38.8%) and third waves
302 179 (48.1%) than in the first wave. Hypertension was prevalent in the second 142 (40.6%) and
303 third wave 208 (55.9%). Asthma 27 (16%), ischemic heart disease 63 (16.9%), and renal disease
304 47 (12.6%) were the most prevalent in the third wave (Table 1).

305 **Symptoms Cluster in COVID-19**

306 We found three clusters of symptoms among the admitted COVID patients: 1. Fever, cough, and
307 respiratory distress. 2. Anosmia, headache, and anorexia 3. Sore throat and running nose. The
308 symptom clusters differed for the three waves. In the first wave, we found three clusters; 1.
309 Respiratory distress and cough. 2. Anosmia and anorexia. 3. Running nose and sore throat. In the
310 second wave, we found a cluster of headaches, running nose, sore throat, and hoarseness of
311 voice. In the third wave, we found three clusters: 1. anorexia and anosmia, 2. fever and cough,
312 and 3. headache, diarrhea, and vomiting. (Figure 1)

313 **Figure 1: Symptoms clusters in COVID-19.**

314 **Table 2: Investigation profile of the admitted patients in the three waves**

315

Variable	Total patient (N)	First wave Median (IQR)	Second wave Median (IQR)	Third wave Median (IQR)	P value
WBC	607	8.50 (6.2-11.72)	18.65 (14.55-24.00)	5.95 (1.28-10.23)	<0.001
Neutrophil (%)	595	71.70 (60.92-83.00)	83.00 (79.0-87.0)	78.00 (68.0-86.0)	<0.001
Lymphocyte (%)	595	21.75 (12.88-30.68)	12.00 (10.70-16.0)	18.00 (10.0-27.0)	<0.001
Platelet count	575	247.00 (189.5-324.0)	126.00 (29.9-276.00)	135.00 (31.00-250.00)	<0.001
CRP	438	12.00 (6.0-34.77)	18.00 (8.68-68.50)	39.00 (13.0-85.0)	<0.001
creatinine	547	0.96 (0.80-1.12)	1.180 (0.95-6.62)	1.14 (0.90-1.40)	<0.001
D-dimer	458	0.47 (0.27-1.05)	1.52 (0.62-3.56)	0.79 (0.40-1.80)	<0.001
Ferritin	369	297.00 (122.0-642.0)	1468.00 (973.5-2050.0)	441.00 (235.5-1000.0)	0.002

Serum sodium	191	-	138.00 (135.0-140.8)	135.00 (132.0-138.0)	0.121
--------------	-----	---	-------------------------	-------------------------	-------

316

317 The white blood cell count was high in the second wave, 18.65(14.5–24), and low in the third
 318 wave. The platelet count was low in the third wave 78 (68–86). CRP was much higher in the
 319 third wave 39 (13–85) and D-dimer 1.52 (0.63–3.56), and ferritin was high in the second wave
 320 1468 (973–2050). (Table 2)

321 **Table 3: Outcome of the admitted patient in three waves**

322

Variable	Categories	Total patient (N)	First wave (N) %	Second wave (N) %	Third wave (N) %	P value
Ultimate severity	Critical	107	32 29.9%	3 2.8%	72 67.3%	<0.001
	Mild	627	365 58.2%	183 29.2%	79 12.6%	
	Moderate	589	383 65.0%	128 21.7%	78 13.2%	
	Severe	271	94 34.7%	32 11.8%	145 53.5%	
Duration of hospital stay			13.0 (8.0-	12.0 (8.0-12.0)	7.0 (4.0-11.0)	<0.001

			20.0)			
Interval symptom onset and admission			5.0 (4.0-6.0)	5.0 (5.0-6.0)	5.0 (4.0-6.0)	<0.001

323

324 The patient developed a more severe disease in the third wave, and the duration of hospital stay
325 was longer in the first wave 12 (8–20). (Table 3)

326

327 **Table 4: Trend of outpatient, inpatient and virology department consultation in three**
328 **waves**

Trait	Total	First wave	Second wave	Third wave	P value
Outpatient department					
Total Attended	38578	19890 (51.6)	7347 (19.0)	11341 (29.4)	
Positive	5584	3134 (15.7%)	896 (12.1%)	1554 (13.7%)	<0.001
Admitted	25721	13650 (68.6%)	5419 (73.7%)	6652 (58.6%)	<0.001
Death	329	127 (0.6%)	105 (1.4%)	97 (0.8%)	
Admission rate (%)	81.3	80.6	84.4	80.1	
Gender					

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

Male					
Total Attended	22595	12274 (54.3)	4341 (19.2)	5980 (26.5)	
Positive	3201	1895 (15.4%)	518 (11.9%)	788 (13.1%)	<0.001
Admitted	15133	8541 (69.5%)	3218 (74.1%)	3374 (56.4%)	<0.001
Death	208	86 (0.7%)	64 (1.4%)	58 (0.9%)	
Admission rate (%)	81.6	81.2	84.7	80.0	
Female					
Total Attended	15981	7614 (47.6)	3006 (18.8)	5361 (33.5)	
Positive	2383	1239 (16.2%)	378 (12.5%)	766 (14.2)	<0.001
Admitted	10586	5107 (67%)	2201 (73.2%)	3278 (61.1%)	<0.001
Death	121	41 (0.5%)	41 (1.3%)	39 (0.6%)	
Admission rate (%)	80.9	80.0	84.0	80.3	
Age group					
<40 years					
Total Attended	14264	7297 (51.2)	2354 (16.5)	4613 (32.3)	
Positive	1623	1021 (13.9)	221 (9.3)	381 (8.2)	<0.001
Admitted	6266	3547 (48.6)	1162 (49.3)	1557 (33.7)	<0.001
Death	49	20 (0.2)	13 (0.5)	16 (0.3)	
Admission rate	79.0	77.3	83.2	79.7	

(%)					
40-60 years					
Total Attended	12759	6920 (54.2)	2457 (19.3)	3382 (26.5)	
Positive	2097	1177 (17)	356 (14.4)	564 (16.6)	<0.001
Admitted	9314	5099 (73.6)	1948 (79.2)	2267 (67)	<0.001
Death	121	42 (0.6)	45 (1.8)	34 (1)	
Admission rate (%)	80.8	80.7	82.9	79.1	
60+ years					
Total Attended	11490	5645 (49.1)	2516 (21.9)	3329 (29.0)	
Positive	1852	929 (16.4)	316 (12.5)	607 (18.2)	<0.001
Admitted	10101	4979 (88.2)	2300 (91.4)	2822 (84.7)	<0.001
Death	153	64 (1.1)	47 (1.8)	42 (1.2)	
Admission rate (%)	83.4	83.4	86.4	81.3	
Inpatient consultation					
Trait	Total	First wave N (%)	Second wave N (%)	Third wave N (%)	P value
Total admission	24501	12797 (52.2)	5317 (21.7)	6387 (26.1)	0.0004
Oxygen support	14198	6865 (48.4)	3332 (23.4)	4001 (28.2)	<0.0001
Percentage of		61.8%	69.43%	75.29%	<0.0001

the patient getting oxygen					
ICU admission	4030	3442 (26.8%)	588 (11%)	---	<0.0001
Death	5057	2584 (20%)	1019 (19%)	1454 (22.7%)	<0.0001
Virology department					
Trait	Total	First wave N (%)	Second wave N (%)	Third wave N (%)	P value
Total population					
Total test	57857	26708 (46.1)	13214 (22.8)	17935 (31.0)	
Positive	12870	5962 (46.3)	2814 (21.9)	4094 (31.8)	<0.001
Positivity rate (%)	22.2%	22.3	21.3	22.8	
Gender					
Male					
Total test	32517	15146 (46.6)	7591 (23.3)	9780 (30.1)	
Positive	7082	3416 (48.2)	1553 (21.9)	2113 (29.8)	<0.001
Positivity rate (%)	21.8	22.6	20.5	21.6	
Female					
Total test	25312	11542 (45.6)	5619 (22.2)	8151 (32.2)	
Positive	5782	2542 (44.0)	1260 (21.8)	1980 (34.2)	<0.001

Positivity rate (%)	22.8	22.0	22.4	24.3	
Age group					
<40					
Total test	27055	13408 (49.6)	5291 (19.6)	8356 (30.9)	
Positive	5555	2721 (49.0)	1063 (19.1)	1771 (31.9)	<0.001
Positivity rate (%)	20.5	20.3	20.1	21.2	
40-60					
Total test	13033	6215 (47.7)	2570 (19.7)	4248 (32.6)	
Positive	3148	1538 (48.9)	582 (18.5)	1028 (32.7)	<0.001
Positivity rate (%)	24.2	24.7	22.6	24.2	
>60					
Total test	8210	3477 (42.4)	1678 (20.4)	3055 (37.2)	
Positive	2114	911 (43.1)	369 (17.5)	834 (39.5)	<0.001
Positivity rate (%)	25.7	26.2	22.0	27.3	

329

330 Confirmed COVID-19 cases were higher (15.7%) in the second wave than in the other waves,
 331 the admission rate 73.7%, and the death rate 1.4% were higher in the second wave than in other
 332 waves. The proportion of confirmed COVID-19 cases was higher among women in all waves. In
 333 the third wave, the admission rate among women 61.1% was higher than among men. The

334 number of positive cases was higher in those below 40 years in the first wave 13.9% and above
335 60 years in the third wave 18.2%. The admission rate of patients below 40 years was lower in the
336 third wave 33.7%. In the second wave, the admission rate among the 40–60-year age group 79%
337 and above 60 years age group 91.4% was higher than in other waves. In the second wave, the
338 death rate was higher among men 1.4% and women, 1.3% In the second wave, the death rate was
339 high in the 40–60-year age group and above 60-year age group. The admission rate was higher in
340 patients aged above 60 years in all three waves.

341 52% of patient were admitted in the first wave and 75% received more oxygen in the third wave.

342 Death was more common 51% in the first wave.

343 The patient was tested more frequently in the first and third waves than in the second wave. The
344 positivity was high in the third wave 22.8%. In the third wave, the positivity rate was high among
345 women 24.3%. The incidence rate of patients above 60 years was high in the first and third
346 waves 27.3%. (Table 4)

347 The daily COVID-19 infection rate was higher in the third wave and the duration of the second
348 wave was short. The first wave lasted longer than the other wave, with an elevated and gradual
349 infection rate decline.

350 The rate of testing was equal for all three waves. The positivity rate was higher during the third
351 than in the first and second waves (Figure 2, Supplement 2).

352

353 **Figure 2: Epidemiologic trend of number of test positivity, hospital admission and death in**
354 **three waves**

355 **Table 5: post COVID -19 complications of the three waves**

Trait	Total patient	First wave	Second wave	Third wave	P value
-------	---------------	------------	-------------	------------	---------

	600	200	200	200	
Age, Mean (SD)	45.2(15.8)	45.5(16.3)	43.6(14.3)	46.5(16.5)	0.19
Sex, Male n (%)	337(56.2)	123(61.5)	97(48.5)	117(58.5)	0.08
Post COVID-19 conditions					
Number of post-covid conditions					0.24
None	40(6.7)	17(8.5)	12(6)	11(5.5)	
Single	93(15.5)	38(19)	30(15.1)	25(12.5)	
Multiple	466(77.7)	145(72.5)	157(78.9)	164(82)	
Symptoms					
Feverish feeling	16(2.7)	6(3)	4(2)	6(3)	0.7
Fatigue	421(70.2)	126(63)	144(72)	151(75.5)	0.03
Cough	127(21.2)	35(17.6)	58(29)	34(17)	0.004
Respiratory distress	40(6.7)	14(7)	15(7.5)	11(5.5)	0.7
Hoarseness of voice	16(2.7)	9(4.5)	2(1)	5(2.5)	0.09
Chest pain	142(23.7)	44(22.1)	40(20.1)	58(29)	0.09
Anorexia	135(22.5)	40(20)	39(19.5)	56(28)	0.07
Anosmia	16(2.7)	7(3.5)	4(2)	5(2.5)	0.6
Headache	146(24.3)	46(23)	49(24.5)	51(25.5)	0.08

Memory disturbance	152(25.4)	46(23)	64(32)	42(21.1)	0.03
Insomnia	73(12.2)	20(10)	29(14.5)	24(11)	0.38
Hypersomnia	4(0.7)	2(1)	2(1)		0.36
Sleep pattern alteration	6(1)	2(1)	2(1)	2(1)	<0.99
Arthralgia	69(11.5)	25(12.6)	28(14)	16(8)	0.15
Confusion	29(4.8)	5(2.5)	12(6)	12(6)	0.18
New onset hypertension	15(2.5)	2(1)	7(3.5)	6(3)	0.23
New onset Diabetes	23(3.8)	8(4)	10(5)	5(2.5)	0.42
Fatigue score, mean (SD)	4.7(2.9)	3.1(2.9)	4.2(3.3)	3.9(3.1)	0.001
Functional status, mean (SD)	90.3(7.4)	90.9(7.7)	90(7.6)	90(6.9)	0.35
Depression	143(25.2)	58(40.6)	49(34.3)	36(25.2)	0.03

356

357 The percentage of patients that developed post-COVID complications was equal in all three
 358 waves. However, patients in the second wave developed more post-covid cough and memory
 359 disturbance depression, and patients in the third wave developed more fatigue than those in other
 360 waves. However, patients in the second wave had increased fatigue scores. The functional status

361 of the patients was similar in the three waves. We found five symptom clusters. However, they
362 did not differ among the three waves (Figure 3).

363 **Figure 3: Symptom cluster in post COVID-state**

364

365

366 **Discussion**

367 This study compared the first, second, and third COVID-19 waves in terms of presentation,
368 outcomes, and hospital epidemiological trends. The first wave lasted longer, and however, the
369 second wave lasted for a short period. We found age and sex differences in the admission rates in
370 the three waves. Cough, runny nose, respiratory distress, diarrhea, vomiting, and anosmia were
371 the most common symptom in the three waves. The symptom cluster differed among the three
372 waves. Disease severity, duration of hospital stay, and severity markers differed. We found
373 disparities in the frequencies of the positivity test and death rates. The three waves had similar
374 Post COVID complications.

375 This study was conducted at the tertiary center of Dhaka. The treatment facility differs from
376 center to center and region to region; therefore, we cannot generalize the findings across the
377 nation and globally.

378 During replication, a mutation in the genetic code of SARS-CoV-2 leads to the development of a
379 new variant. The behaviors of variants, such as virulence and transmissibility, differ [28]. WHO
380 named the variant to be monitored with the Greek alphabet and named from alpha to zeta [29]. In
381 Bangladesh, until September 2021, alpha, beta, and delta variants were dominant at different
382 times creating, three waves of COVID-19: the first wave was caused by alpha, the second wave

383 was caused by beta, and the third wave caused by delta variants [18]. Epidemiological and
384 disease characteristics differ in various studies [16,30,31].

385 In Bangladesh, the first wave lasted approximately 8 months, the second wave approximately 2
386 months, and the third wave approximately 3 months. This was due to the variations'
387 transmissibility; delta was 63–167% more transmissible than alpha [32]. Therefore, the most
388 susceptible people became infected faster, replacing existing variants. Delta and beta variants
389 spread quickly in Bangladesh, and delta quickly became the dominant variant. Omicron was 2.8
390 times more transmissible than Delta, thus replacing Delta in a short period [33].

391 In this study, we found a variation in the demographic patterns across the three variants.

392 Young people were more affected in the initial wave, as evidenced by the high number of
393 positive cases in the virology laboratory among the young. However, the elderly had a higher
394 positivity rate. The proportion of older adult patients in the hospitalized patients was higher in
395 the first and third waves than in the second wave. The admission rate among the attended
396 patients in the outpatient department was higher in the second wave than in the first and third
397 waves. Because of their increased mobility the younger age group became infected in large
398 numbers. Immune senescence and various comorbidities could explain the older adults'
399 admission. The viral receptors ACE2 and CD26 are more expressed in senescent cells, which
400 explains why older adults are more susceptible to infection [35]. The virus affinity for the
401 receptor varies among the variants. This explains the age group variations among variants [36].

402

403 The overall number of admitted men was higher than women. However, the number of women
404 admitted was higher in the second wave. Admission and death rates were higher among men.
405 However,, women had a higher positivity rate than men, especially in the second and third

406 waves. Men had higher rate of incidence of COVID-19 due to the altered immunologic response,
407 associated comorbidity, hormonal differences, and smoking habits [35]. angiotensin-converting
408 enzyme (ACE) receptor expression is higher in women because its genetic loci are on the X
409 chromosome [37]. The *TMPRSS2* gene is located on chromosome 21q22.3[38]. Some variants
410 have a higher affinity for TMPRSS than for ACE II. This might explain the gender differences in
411 the expression of the various COVID-19 variants. Again, increased testosterone levels may
412 increase the probability of microthrombi formation [39], which is the underlying
413 pathophysiology of severe COVID-19.

414 The duration of Hospital admission was longer in the first wave, which was most likely due to
415 the severity of the disease at the time of discharge. In the first wave, most patients were admitted
416 because of isolation, and their release was determined by the time of PCR negativity. ICU
417 admission was higher in the first wave due fear an unnecessary patient transfer to the ICU. The
418 death rate was higher in the third wave than in other waves.

419 The different affinities of the viruses can explain the heterogeneous presentation and clustering
420 of various variants to the receptor. The virus's ability to escape immunity [40] can explain the
421 mutant strain's varied presentation and severity.

422 The three waves had slightly different post-COVID-19 complications. Further studies on its
423 pathogenesis and immunological response are needed.

424 Because this was a single-center study, genotyping was either not performed or was impractical
425 for all patients. This was a retrograde study and a review of the documents. Therefore, missing
426 information was likely.

427 **Conclusion**

428 This study revealed that during the COVID-19 waves, the presenting features, outcomes, and
429 epidemiologic trends were different.

430 **Recommendation**

431 In each of the three waves, COVID-19 occurred differently. A mutant strain of the SARS-CoV-2
432 was most likely the cause of these differences. Therefore, we recommend the following.

- 433 1. There should be genetic surveillance for the identification of the specific variant
434 of interest.
- 435 2. At the onset of each wave, intensive epidemiologic surveillance should be
436 conducted.
- 437 3. There should be diversity in each wave's strategy for disease control planning,
438 treatment, and hospital management.

439 **Acknowledgments**

440 We are grateful to Dhaka Medical College Hospital authority for giving us permission to access
441 the hospital records; without their help it will be impossible to conduct this study.

442

443 **References:**

- 444 1. World Health Organization. GCM teleconference – Note for the Records. 10 January
445 2020. Subject: Pneumonia in Wuhan, China. Available from: [https://www.who.int/
446 blueprint/10-01-2020-nfr-gcm.pdf?ua=](https://www.who.int/blueprint/10-01-2020-nfr-gcm.pdf?ua=).

- 447 2. World Health Organization. Novel coronavirus (2019-nCoV). Situation Report – 1. 21
448 January 2020. Available from: [https://www.who.int/docs/default-source_/coronaviruse](https://www.who.int/docs/default-source_/coronaviruse/situation-reports/20200121-sitrep-1-2019-ncov.pdf?sfvrsn=20a99c10_4)
449 [/situation-reports/20200121-sitrep-1-2019-ncov.pdf?sfvrsn=20a99c10_4](https://www.who.int/docs/default-source_/coronaviruse/situation-reports/20200121-sitrep-1-2019-ncov.pdf?sfvrsn=20a99c10_4).
- 450 3. WHO Director-General's opening remarks at the media briefing on COVID-19 - 11
451 March 2020, available from: [https://www.who.int/dg/speeches/detail/who-director-](https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020)
452 [general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020](https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020).
- 453 4. <https://www.worldometers.info/coronavirus/>, Accessed 25 November 2021.
- 454 5. [https://www.who.int/influenza/resources/documents/pandemic_phase_descriptions_and_](https://www.who.int/influenza/resources/documents/pandemic_phase_descriptions_and_actions.pdf)
455 [actions.pdf](https://www.who.int/influenza/resources/documents/pandemic_phase_descriptions_and_actions.pdf). Accessed 25 November 2021.
- 456 6. <https://www.history.com/news/pandemics-end-plague-cholera-black-death-smallpox>.
457 Accessed 25 November 2021
- 458 7. Kissler SM, Tedijanto C, Goldstein E, Grad YH, Lipsitch M. **Projecting the**
459 **transmission dynamics of SARS-CoV-2 through the postpandemic period.**
460 *Science* 22 May 2020:Vol. 368, Issue 6493, pp. 860-868. DOI: 10.1126/science.abb5793
- 461 8. [https://www.theguardian.com/world/2021/mar/22/lockdowns-return-extended-third-](https://www.theguardian.com/world/2021/mar/22/lockdowns-return-extended-third-wave-covid-europe)
462 [wave-covid-europe](https://www.theguardian.com/world/2021/mar/22/lockdowns-return-extended-third-wave-covid-europe). Accessed 25 November 2021.
- 463 9. <https://time.com/5951490/covid-fourth-wave/> Accessed 25 November 2021.
- 464 10. <https://www.who.int/csr/don/31-december-2020-sars-cov2-variants/en/> Accessed 25
465 November 2021.
- 466 11. <https://www.nature.com/articles/d41586-020-02544-6>. Accessed 25 November 2021.
- 467 12. <https://www.who.int/csr/don/31-december-2020-sars-cov2-variants/en/>. Accessed 25
468 November 2021.

- 469 13. [European Centre for Disease Prevention and Control 20 Dec 2020 Threat Assessment](#)
470 [Brief](#). Accessed 25 November 2021.
- 471 14. [https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/scientific-brief-](https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/scientific-brief-emerging-variants.html)
472 [emerging-variants.html](https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/scientific-brief-emerging-variants.html). Accessed 19 November 2021.
- 473 15. [https://www.who.int/docs/default-source/coronaviruse/situation](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20210427-weekly-epi-update-37.pdf?sfvrsn=a1ab459c_5&download=true)
474 [reports/20210427_weekly_epi_update_37.pdf?sfvrsn=a1ab459c_5&download=true](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20210427-weekly-epi-update-37.pdf?sfvrsn=a1ab459c_5&download=true).
475 Accessed 19 November 2021.
- 476 16. Ranjan, R., Sharma, A., Verma, M.K., 2021. Characterization of the Second Wave of
477 COVID-19 in India. medRxiv 2021.04.17.21255665. doi: 10.1101/2021.04.17.21255665
- 478 17. [https://www.tbsnews.net/coronavirus-chronicle/covid-19-bangladesh/covid-deaths-drop-](https://www.tbsnews.net/coronavirus-chronicle/covid-19-bangladesh/covid-deaths-drop-41-lowest-39-days-242425)
479 [41-lowest-39-days-242425](https://www.tbsnews.net/coronavirus-chronicle/covid-19-bangladesh/covid-deaths-drop-41-lowest-39-days-242425). Accessed 19 November 2021.
- 480 18. <https://www.icddrb.org/news-and-events/icddrb-in-the-news>. Accessed 19 November
481 2021.
- 482 19. WHO guidance on management of severe acute respiratory infection (SARI) when
483 COVID19 is suspected. Accessed November 1, 2020. [//www.who.int/publications-](https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected)
484 [detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-](https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected)
485 [coronavirus-\(ncov\)-infection-is-suspected](https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected).
- 486 20. National Guidelines on Clinical Management of Coronavirus Disease 2019 (COVID-19).
487 27 May, 2020. Accessed November 1, 2020. [https://dghs.gov.bd/images/docs/Guideline/](https://dghs.gov.bd/images/docs/Guideline/COVID.Guideline.pdf)
488 [COVID.Guideline.pdf](https://dghs.gov.bd/images/docs/Guideline/COVID.Guideline.pdf).
- 489 21. Bari R and Sultana F (2021) Second Wave of COVID-19 in Bangladesh: An Integrated
490 and Coordinated Set of Actions Is Crucial to Tackle Current Upsurge of Cases and
491 Deaths. Front. Public Health 9:699918. doi: 10.3389/fpubh.2021.699918

- 492 22. Devnath P, Hossain MJ, Emran TB, Mitra S. Massive third wave of COVID-19 outbreak
493 in Bangladesh: a co-epidemic of dengue might worsen the situation. *Future Virol.* 2022
494 Jan;10.2217/fvl-2021-0182. doi: 10.2217/fvl-2021-0182. Epub 2022 Mar 8. PMID:
495 35284001; PMCID: PMC8906578.
- 496 23. Post-COVID conditions. Centers for disease control and prevention, USA. Accessed 19
497 July 2021. From [https://www.cdc.gov/coronavirus/2019-ncov/long-term-](https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html)
498 [effects/index.html](https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html)
- 499 24. Committee on the Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue
500 Syndrome; Board on the Health of Select Populations; Institute of Medicine. *Beyond*
501 *Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness.*
502 Washington (DC): National Academies Press (US); 2015 Feb 10. Available from:
503 <https://www.ncbi.nlm.nih.gov/books/NBK274235/> DOI: 10.17226/19012.
- 504 25. [Chalder, T.](#); [Berelowitz, G.](#); [Pawlikowska, T.](#); [Watts, L.](#); [Wessely, S.](#); [Wright, D.](#);
505 [Wallace, E. P.](#) (1993). ["Development of a fatigue scale"](#). *Journal*
506 *of Psychosomatic Research.* **37** (2): 147–153. [ISSN 0022-3999.](#) [PMID 8463991](#)
- 507 26. Karnofsky D, Burchenal J, The clinical evaluation of chemotherapeutic agents in cancer.
508 In: MacLeod C, ed. *Evaluation of Chemotherapeutic Agents.* New York, NY: Columbia
509 University Press; 1949:191–205.
- 510
- 511 27. Kroenke, K., Spitzer, R. L., & Williams, J. B. (2001). The PHQ-9: validity of a brief
512 depression severity measure. *Journal of general internal medicine,* **16**(9), 606–613.
513 <https://doi.org/10.1046/j.1525-1497.2001.016009606.x>

- 514 28. Islam S, Islam T, Islam MR. New Coronavirus Variants are Creating More Challenges to
515 Global Healthcare System: A Brief Report on the Current Knowledge. *Clin Pathol*. 2022
516 Feb 3;15:2632010X221075584. doi: 10.1177/2632010X221075584. PMID: 35141522;
517 PMCID: PMC8819824.
- 518 29. <https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-classifications>. Accessed on
519 01.11.21
- 520 30. S. Iftimie, A. F. López-Azcona, I. Vallverdú et al., “First and second waves of
521 coronavirus disease-19: a comparative study in hospitalized patients in Reus,
522 Spain,” *PLoS One*, vol. 16, no. 3, Article ID e0248029, 2021.
- 523 31. Kunno J, Supawattanabodee B, Sumanasrethakul C, Wiriyasivaj B, Kuratong S,
524 Kaewchandee C. Comparison of Different Waves during the COVID-19 Pandemic:
525 Retrospective Descriptive Study in Thailand. *Adv Prev Med*. 2021 Oct 8; 2021:5807056.
526 doi: 10.1155/2021/5807056. PMID: 34659835; PMCID: PMC8519693.
- 527 32. Earnest, R, Uddin, R, Matluk, N, et al. Comparative transmissibility of SARS-CoV-2
528 variants Delta and Alpha in New England, USA. *Cell Rep*
529 *Med*. 2022;3(4):100583. <https://doi.org/10.1016/j.xcrm.2022.100583>
- 530 33. De La Cruz-Hernández, S., & Álvarez-Contreras, A. (2022). Omicron Variant in Mexico:
531 The Fourth COVID-19 Wave. *Disaster Medicine and Public Health Preparedness*, 1-2.
532 doi:10.1017/dmp.2022.160
- 533 34. Monod M, Blenkinsop A, Xi X, Hebert D, Bershian S, Tietze S, Baguelin M, Bradley VC,
534 Chen Y, Coupland H, Filippi S, Ish-Horowicz J, McManus M, Mellan T, Gandy A,
535 Hutchinson M, Unwin HJT, van Elsland SL, Vollmer MAC, Weber S, Zhu H, Bezancon
536 A, Ferguson NM, Mishra S, Flaxman S, Bhatt S, Ratmann O; Imperial College COVID-

- 537 19 Response Team. Age groups that sustain resurging COVID-19 epidemics in the
538 United States. *Science*. 2021 Mar 26;371(6536):eabe8372. doi: 10.1126/science.
539 abe8372. Epub 2021 Feb 2. PMID: 33531384; PMCID: PMC8101272.
- 540 35. Al-Bari MAA, Hossain S, Zahan MK. Exploration of sex-specific and age-dependent
541 COVID-19 fatality rate in Bangladesh population. *World J Radiol*. 2021 Jan 28;13(1):1-
542 18. doi: 10.4329/wjr.v13.i1.1. PMID: 33574990; PMCID: PMC7852349.
- 543 36. Han Y, Wang Z, Wei Z, Schapiro I, Li J. Binding affinity and mechanisms of SARS-
544 CoV-2 variants. *Comput Struct Biotechnol J*. 2021; 19:4184-4191. doi:
545 10.1016/j.csbj.2021.07.026. Epub 2021 Jul 26. PMID: 34336146; PMCID:
546 PMC8312055.
- 547 37. Schurz H, Salie M, Tromp G, Hoal EG, Kinnear CJ, Möller M. The X chromosome and
548 sex-specific effects in infectious disease susceptibility. *Hum Genomics*. 2019; **13:2**.
- 549 38. Stopsack KH, Mucci LA, Antonarakis ES, Nelson PS, Kantoff PW. *TMPRSS2* and
550 COVID-19: Serendipity or Opportunity for Intervention? *Cancer Discov*. 2020; **10:779–**
551 **782**.
- 552 39. Walker RF, Zakai NA, MacLehose RF, Cowan LT, Adam TJ, Alonso A, Lutsey PL.
553 Association of Testosterone Therapy With Risk of Venous Thromboembolism Among
554 Men With and Without Hypogonadism. *JAMA Intern Med*. 2020; **180:190–197**.
- 555 40. Liu H, Wei P, Kappler JW, Marrack P, Zhang G. SARS-CoV-2 Variants of Concern and
556 Variants of Interest Receptor Binding Domain Mutations and Virus Infectivity. *Front*
557 *Immunol*. 2022 Jan 27; 13:825256. doi: 10.3389/fimmu.2022.825256. PMID: 35154144;
558 PMCID: PMC8828474.
- 559

560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581

Supporting Information:

1. Supplement 1: Patient selection and distribution of the patient for this cross-sectional study
2. Supplement 2: Difference in daily oxygen support, daily positive cases and daily test variability in three waves

It is made available under a [CC-BY 4.0 International license](#) .

582

583

584

585

586

587

588

589

590

591

592

593

594

595

596

597

598

599

600

601

602

603

It is made available under a [CC-BY 4.0 International license](#) .

604

605

606

607







Figure 1

Figure 1: Symptoms clusters in COVID-19


- a. According to general clusters of symptoms, We found three clusters of symptoms among the admitted patients with COVID-19: 1. Fever, cough, and respiratory distress. 2. Anosmia, headache, and anorexia, 3. Sore throat and running nose. b . In the first wave, we found three clusters 1. Respiratory distress and cough, 2. Anosmia anorexia, and 3. Running nose and sore throat. c. In the second wave, we found a cluster headache, running nose, sore throat, and hoarseness of voice. d. In the third wave, we found three clusters 1. Anorexia and anosmia, 2. Fever and cough, and 3. headache, diarrhea, and vomiting.

medRxiv preprint doi: <https://doi.org/10.1101/2022.12.14.22283379>; this version posted December 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).
We did the network analysis with tidy verse and q graph using R (v4.1.1).

(cov-COVID-19, Fvr-Fever, Cgh-cough, Rnn-Running nose, Rsd-Respiratory distress, Srt-Sore throat, Hrv-Hoarseness of voice, Chp-Chest pain, Drr- Diarrhea, Vmt-vomiting, Anr-Anorexia, Ans: Anosmia, Hdc-Headache, Lth-Lethargy, Ach-Body ache)


Daily Covid-19 affected trend during 3 phases



a medRxiv preprint doi: <https://doi.org/10.1101/2022.12.14.22283379>; this version posted December 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.


It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Covid-19 patient admission trend during 3 waves



b

Daily during 3 waves of Covid-19



c

Figure 2

Figure 2: Epidemiologic trend of number of test positivity, hospital admission and death in three surges

- a. Test positivity-The first surge remained longer and the second surge was narrowest. The daily number of positive cases was high in the second and third surge.
- b. Daily admission-Number of daily admissions was highest in the initial part of the first wave and third wave
- c. Daily death-Number of daily deaths was highest in the initial part of the first wave and third wave

(The first, second, and third waves extend from April 2020 to January 2020, February 2021 to May 2021, and June 2021 to September 2021, respectively)

medRxiv preprint doi: <https://doi.org/10.1101/2022.12.14.22283379>; this version posted December 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .




Figure 3

Figure 3: Symptom cluster in post COVID-state

There were five cluster of symptoms in the post-COVID state, 1-diarrhea and vomiting, 2-fatigue and anorexia, 3-memory loss and insomnia, 4-persistent cough and sputum, 5-sore throat and respiratory distress.

We did the network analysis with tidy verse and q graph using R (v4.1.1). (cov-COVID-19, Ftg-Fatigue, Ptc- persistent cough, Spt-sputum, Rsd-Respiratory distress, Srt-Sore throat, Chp-Chest pain, Drr- Diarrhea, Vmt-vomiting, Anr-Anorexia, Ans: Anosmia, Hdc-Headache, NHT: new onset hypertension, NDM: new onset diabetes, Mmd-Memory disturbance

medRxiv preprint doi: <https://doi.org/10.1101/2022.12.14.22283379>; this version posted December 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .